Bordeaux, Boston, may 10, 2017, 8: 00 am IMPLANET (Euronext : IMPL, FR0010458729, eligible PEA-PME), a medical technology company specializing in spinal implants and implants for knee surgery, announced today the participation of its management of the international conference, OTC QX Virtual Investor, which will be held on Thursday, 11 May at 12: 00 CEST.
Download the free guide
Boost your gains
Ludovic Lastennet, ceo of Implanet will present this Thursday, 11 May at 12: 00 an overview of the activities of the company and its recent results. If you want to participate in the international conference OTC QX, the Virtual Investor, you can register for free at :
http://tinyurl.com/0511agendaPR.
If you can’t be present, you can still view the webcast archives. These will also be available on www.VirtualInvestorConferences.com after the event.
About OTC Markets Group
OTC Markets Group Inc. (OTCQX: OTCM) operates the market, OTCQX® Best Market, the market, OTCQB® Venture market and Open Pink® for 10 000 values, us and international. Through OTC Link® ATS, the group connects a diverse network of brokers who provides a service of liquidity and execution. OTC Markets also allows investors to freely trade with the broker of their choice, and empower businesses to improve the quality of information available to investors. OTC Link ATS is operated by OTC Link LLC, member FINRA / SIPC and SEC regulated ATS.
OTC Markets Group, in partnership with VirtualInvestorConferences.com, a company of the group, PR Newswire and Better Investing TM will host the seventh edition of a series of online investors to the companies listed on the OTCQX Best Market.
Next press release : revenue for Q2 2017 July 18, 2017
About IMPLANET
Founded in 2007, IMPLANET is a medical technology company manufacturer of implants, top of the range for orthopaedic surgery. Its flagship product, the implant of the latest generation JAZZ, is intended to improve the treatment of spinal disorders that require spinal fusion. The platform of orthopedics with proven IMPLANET, based on a perfect control of the traceability of its products, gives it a proven ability to enhance the value of this innovation. Protected by 4 families of international patents, JAZZ has obtained regulatory approval 510(k) of the Food and Drug Administration (FDA) in the United States, the CE marking and the authorization of Anvisa in Brazil. IMPLANET employs 48 staff and has a turnover of € 7.8 million in 2016. More information on www.implanet.com.
Based near Bordeaux in France, IMPLANET has been open since 2013 a subsidiary in the United States (Boston). IMPLANET is listed on compartment C of the regulated market of Euronext in Paris.
Download the free guide
Boost your gains
